Schlieren ZH/Anaheim – Biognosys announces the market launch of its new P2 plasma enrichment technology. The method will be presented on June 3 at the annual conference of the American Society of Mass Spectrometry (ASMS).
The Schlieren-based biotech company Biognosys presents the patent-protected P2 plasma enrichment method. It uses a novel single-particle method to achieve unbiased, in-depth mass spectrometry-based plasma proteomics, according to a press release. P2 plasma enrichment is available as a contract research organization (CRO) service via the Biognosys TrueDiscovery platform or as an in-house method for users via licensing.
"With our proprietary P2 Plasma Enrichment method, Biognosys can now significantly increase the depth and throughput of plasma proteomics beyond what previous methods could achieve," said Oliver Rinner, CEO and founder of Biognosys. "Most importantly, this advance comes with exceptional reproducibility, which is critical for quantitative studies. It also offers superior cost-effectiveness, achieving a false discovery rate of less than 1 percent, which cannot be achieved with expensive, highly complex affinity-based methods."
The P2 plasma enrichment method is offered as a contract research service by the Biognosys facilities in Schlieren and at the company's US headquarters in Newton, Massachusetts, via the TrueDiscovery platform.
The technical features and performance data will be presented at the annual conference of the American Society of Mass Spectrometry (ASMS) in Anaheim, California, on Monday, June 3, during a Biognosys breakfast seminar and on Wednesday, June 5, during a poster session.
Biognosys is a spin-off from the Swiss Federal Institute of Technology in Zurich(ETH) and is based in the Bio-Technopark Schlieren-Zurich. ce/gba